Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
121.88
-0.75 (-0.61%)
At close: Jun 26, 2026, 4:00 PM EDT
116.88
-5.00 (-4.10%)
After-hours: Jun 26, 2026, 6:03 PM EDT
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Protagonist Therapeutics stock have an average target of 117, with a low estimate of 100 and a high estimate of 137. The average target predicts a decrease of -4.00% from the current stock price of 121.88.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 9 | 9 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 22, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $97 → $110 | Hold | Maintains | $97 → $110 | -9.75% | Jun 11, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $106 → $113 | Buy | Maintains | $106 → $113 | -7.29% | May 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $117 | Buy | Reiterates | $117 | -4.00% | May 11, 2026 |
| Citi | Citi | Buy Maintains $125 → $130 | Buy | Maintains | $125 → $130 | +6.66% | May 10, 2026 |
Financial Forecast
Revenue This Year
509.21M
from 46.02M
Increased by 1,006.59%
Revenue Next Year
159.78M
from 509.21M
Decreased by -68.62%
EPS This Year
4.17
from -2.05
EPS Next Year
-0.68
from 4.17
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 586.6M | 261.9M | |
| Avg | 509.2M | 159.8M | |
| Low | 129.0M | 81.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1,174.8% | -48.6% | |
| Avg | 1,006.6% | -68.6% | |
| Low | 180.3% | -84.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.88 | 2.01 | |
| Avg | 4.17 | -0.68 | |
| Low | -1.00 | -2.33 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | -51.9% | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.